ReviewBiomedical engineering online2025
Advancing ADMET prediction for major CYP450 isoforms: graph-based models, limitations, and future directions.
Review in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision.Pharmacopsychiatry · 2026Review
- AI-Integrated QSAR Modeling for Enhanced Drug Discovery: From Classical Approaches to Deep Learning and Structural Insight.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding Cytochrome P450 (CYP) enzyme-mediated metabolism is critical for accurate Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictions, which play a pivotal role in drug discovery. Traditional approaches, while foundational, often face challenges related to cost, scalability, and translatability. This review provides a comprehensive exploration of how graph-based computational techniques, including Graph Neural Networks (GNNs), Graph Convolutional Networks (GCNs) and Graph Attention Networks (GATs), have emerged as powerful tools for modeling complex CYP enzyme interactions and predicting ADMET properties with improved precision. Focusing on key CYP isoforms-CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4-we synthesize current research advancements and methodologies, emphasizing the integration of multi-task learning, attention mechanisms, and explainable AI (XAI) in enhancing the accuracy and interpretability of ADMET predictions. Furthermore, we address ongoing challenges, such as dataset variability and the generalization of models to novel chemical spaces. The review concludes by identifying future research opportunities, particularly in improving scalability, incorporating real-time experimental validation, and expanding focus on enzyme-specific interactions. These insights underscore the transformative potential of graph-based approaches in advancing drug development and optimizing safety evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.